EVO vs PCRX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 20, 2026

EVO

45.7
AI Score
VS
PCRX Wins

PCRX

59.8
AI Score

Investment Advisor Scores

EVO

46score
Recommendation
HOLD

PCRX

60score
Recommendation
STRONG BUY

AI Analyst Insights

Detailed Metrics Comparison

Metric EVO PCRX Winner
Forward P/E 53.4759 8.4531 PCRX
PEG Ratio 1.4223 11.2121 EVO
Revenue Growth -16.2% 6.2% PCRX
Earnings Growth 0.0% -30.0% EVO
Tradestie Score 45.7/100 59.8/100 PCRX
Profit Margin -27.5% 2.0% PCRX
Beta 1.00 1.00 Tie
AI Recommendation HOLD STRONG BUY PCRX

Relative Price Performance (Last 90 Days)

EVO 1M: -2.6% · 3M: -37.6% PCRX 1M: -3.9% · 3M: +6.5%

Current Technical Phase

EVO

Markdown
Sell / avoid

Price below a falling SMA50 (slope -13.4%), weak momentum, RSI 37

RSI (14): 37.3 · Price: $1.89

PCRX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 51

RSI (14): 51.0 · Price: $24.86

Fundamentals Snapshot

Metric EVO PCRX
Market Cap
Forward P/E -5.0 6.9
Trailing P/E 67.7
Revenue (TTM)
Revenue Growth -0.2% 0.1%
Gross Margin 0.1% 0.8%
Operating Margin -0.6% 0.1%
EPS -0.65 0.36
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, PCRX is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.